Clinical Trials Browser

Stomach Neoplasms

NCT05755048 2023-09-01

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

314 enrolled

Breast

Breast Neoplasms

NCT03958890 2023-04-18

A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Phase 3 Unknown

489 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05753865 2023-03-03

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

Phase 3 Unknown

454 enrolled

Breast

Advanced Breast Cancer

NCT04840290 2021-04-21

A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

Phase 3 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02667743 2021-03-17

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Phase 3 Unknown

454 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04568304 2020-09-29

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Phase 3 Unknown

364 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Phase 3 Unknown

332 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3 Unknown

762 enrolled

Thoracic

PD-L1 Positive Non-small Cell Lung Cancer

NCT04185649 2019-12-04

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Phase 3 Unknown

410 enrolled

Breast

HER2-positive Advanced Breast Cancer

NCT01681446 2018-06-01

Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression

Phase 3 Unknown

296 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03516448 2018-05-04

Expanding Phase III Study of Tyroserleutide for Injection

Phase 3 Unknown

352 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03439709 2018-03-01

MERGE

Phase 3 Unknown

90 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT03083743 2017-03-20

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Phase 3 Unknown

417 enrolled

Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Thoracic Neoplasms

Clinical Trials

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression

Expanding Phase III Study of Tyroserleutide for Injection

MERGE

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection